Faruqi and Faruqui, LLP Logo
Share this page

Durata Therapeutics Inc. (DRTX)

(NasdaqGM: DRTX)

Summary

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. (“Durata” or the “Company”) (NasdaqGM: DRTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Actavis plc for approximately $675 million.  The Company’s stockholders will only receive $23.00 for each share of Durata common stock they own, when according to Yahoo! Finance at least one analyst has set a price target of $26.00 for the Company. The deal price might be $5.00 higher based on a contingency-milestone basis.

The investigation focuses on whether Durata’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales pwsrocess and whether and by how much this proposed transaction undervalues the Company to the detriment of Durata’s shareholders.

If you own common stock in Durata and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Durata Therapeutics Inc. (DRTX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 10/06/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.